Compare SOTK & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SOTK | NRXS |
|---|---|---|
| Founded | 1975 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.0M | 82.0M |
| IPO Year | 1995 | 2023 |
| Metric | SOTK | NRXS |
|---|---|---|
| Price | $4.25 | $5.47 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $8.50 | ★ $11.00 |
| AVG Volume (30 Days) | 105.0K | ★ 162.9K |
| Earning Date | 10-14-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.50 | 22.13 |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $20,909,315.00 | $3,569,282.00 |
| Revenue This Year | $2.67 | $118.53 |
| Revenue Next Year | $23.22 | $101.28 |
| P/E Ratio | $62.14 | ★ N/A |
| Revenue Growth | 1.97 | ★ 32.89 |
| 52 Week Low | $3.40 | $2.21 |
| 52 Week High | $7.48 | $9.33 |
| Indicator | SOTK | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 32.35 | 31.79 |
| Support Level | $4.25 | N/A |
| Resistance Level | $4.62 | $7.79 |
| Average True Range (ATR) | 0.28 | 0.54 |
| MACD | -0.06 | -0.18 |
| Stochastic Oscillator | 11.03 | 2.94 |
Sono-Tek Corp designs and manufactures ultrasonic coating systems for applying precise, thin film coatings to add functional properties, protect or strengthen surfaces on parts and components for the microelectronics/electronics, alternative energy, medical, industrial, and emerging research & development/other markets. The company designs and manufacture custom-engineered ultrasonic coating systems incorporating its patented technology, in combination with applications engineering knowledge, to assist its customers in achieving their desired coating solutions.
Neuraxis Inc is a growth-stage medical technology company focused on neuromodulation therapies for chronic and debilitating conditions in the gastrointestinal (GI) digestive system, specifically from disorders of the gut-brain interaction (DGBIs) in pediatrics and adults. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).